A. P. Schachat, L. Hyman, M. C. Leske, A. M. Connell, and S. Y. Wu, Features of age-related macular degeneration in a black population. The Barbados Eye Study Group, Arch Ophthalmol Chic Ill, vol.113, pp.728-763, 19601995.

W. L. Wong, X. Su, X. Li, C. Cheung, R. Klein et al., Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, Lancet Glob Health, vol.2, issue.13, pp.70145-70146, 2014.

C. A. Augood, J. R. Vingerling, P. De-jong, U. Chakravarthy, J. Seland et al., Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE), Arch Ophthalmol Chic Ill, vol.124, pp.529-564, 1960.

U. Chakravarthy, C. Augood, G. C. Bentham, P. De-jong, M. Rahu et al.,

, Cigarette smoking and age-related macular degeneration in the EUREYE Study, Ophthalmology, vol.114, pp.1157-63, 2007.

R. Klein, T. Peto, A. Bird, and M. R. Vannewkirk, The epidemiology of age-related macular degeneration, Am J Ophthalmol, vol.137, pp.486-95, 2004.

A. P. Schachat, L. Hyman, M. C. Leske, A. M. Connell, and S. Y. Wu, Features of age-related macular degeneration in a black population. The Barbados Eye Study Group, Arch Ophthalmol Chic Ill, vol.113, pp.728-763, 19601995.

R. Klein, B. E. Klein, and K. J. Cruickshanks, The prevalence of age-related maculopathy by geographic region and ethnicity, Prog Retin Eye Res, vol.18, pp.371-89, 1999.

W. Smith, J. Assink, R. Klein, P. Mitchell, C. C. Klaver et al., Risk factors for age-related macular degeneration: Pooled findings from three continents, Ophthalmology, vol.108, pp.697-704, 2001.

F. Jonasson, D. E. Fisher, G. Eiriksdottir, S. Sigurdsson, R. Klein et al., Fiveyear incidence, progression, and risk factors for age-related macular degeneration: the age, gene/environment susceptibility study, Ophthalmology, vol.121, pp.1766-72, 2014.

M. G. Krzystolik, M. A. Afshari, A. P. Adamis, J. Gaudreault, E. S. Gragoudas et al., Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment, Arch Ophthalmol Chic Ill, vol.120, pp.338-384, 1960.

R. Klein, B. E. Klein, S. C. Jensen, and S. M. Meuer, The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study, Ophthalmology, vol.104, pp.7-21, 1997.

, Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration, Arch Ophthalmol Chic Ill, vol.111, pp.1200-1209, 19601993.

, Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two

P. Mitchell, N. Bressler, Q. V. Doan, C. Dolan, A. Ferreira et al., Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment, PloS One, vol.9, p.101072, 2014.

N. Ferrara, R. D. Mass, C. Campa, and R. Kim, Targeting VEGF-A to treat cancer and agerelated macular degeneration, Annu Rev Med, vol.58, pp.491-504, 2007.

A. P. Dm, H. Yue, T. Ianchulev, and S. Schneider, Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1, Am J Ophthalmol, vol.145, pp.239-287, 2008.

. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER study year 2, Am J Ophthalmol, vol.150, pp.315-324, 2010.

D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy et al., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study, Ophthalmology, vol.116, pp.57-65, 2009.

D. M. Brown, P. K. Kaiser, M. Michels, G. Soubrane, J. S. Heier et al.,

, Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N Engl J Med, vol.355, pp.1432-1476, 2006.

U. Schmidt-erfurth, B. Eldem, R. Guymer, J. Korobelnik, and R. O. Schlingemann,

R. Siegel, Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study, Ophthalmology, vol.118, pp.831-840, 2011.

U. Schmidt-erfurth, P. K. Kaiser, J. Korobelnik, D. M. Brown, V. Chong et al., Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninetysix-week results of the VIEW studies, Ophthalmology, vol.121, pp.193-201, 2014.

M. A. Singer, C. C. Awh, S. Sadda, W. R. Freeman, A. N. Antoszyk et al., HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration, Ophthalmology, vol.119, pp.1175-83, 2012.

A. C. Ho, B. G. Busbee, C. D. Regillo, M. R. Wieland, S. A. Van-everen et al., Twentyfour-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration, Ophthalmology, vol.121, pp.2181-92, 2014.

O. P. Gupta, G. Shienbaum, A. H. Patel, C. Fecarotta, R. S. Kaiser et al., A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact, Ophthalmology, vol.117, pp.2134-2174, 2010.

F. Abedi, S. Wickremasinghe, A. Islam, K. M. Inglis, and R. H. Guymer, Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years, Retina Phila Pa, vol.34, pp.1531-1539, 2014.

K. B. Freund, J. Korobelnik, R. Devenyi, C. Framme, J. Galic et al., RETINAL DISEASES: A Literature Review and Consensus Recommendations, vol.35, pp.1489-506, 2015.

N. Rayess, S. Houston, O. P. Gupta, A. C. Ho, and C. D. Regillo, Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen, Am J Ophthalmol, vol.159, pp.3-8, 2015.

C. Gianniou, A. Dirani, W. Ferrini, L. Marchionno, D. Decugis et al., Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results, Eye Lond Engl, vol.29, pp.450-451, 2015.

P. Parvin, M. Zola, A. Dirani, A. Ambresin, and I. Mantel, Two-year outcome of an observeand-plan regimen for neovascular age-related macular degeneration treated with Aflibercept

, Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol, vol.255, pp.2127-2161, 2017.

R. Spaide, Ranibizumab according to need: a treatment for age-related macular degeneration, Am J Ophthalmol, vol.143, pp.679-80, 2007.

R. Silva, A. Berta, M. Larsen, W. Macfadden, C. Feller et al., Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study, Ophthalmology, vol.125, pp.57-65, 2018.

C. C. Wykoff, D. E. Croft, D. M. Brown, R. Wang, J. F. Payne et al., Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results, Ophthalmology, vol.122, pp.2514-2536, 2015.

D. Barthelmes, V. Nguyen, V. Daien, A. Campain, R. Walton et al., Two year outcomes of « TREAT AND EXTEND » intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration, Retina Phila Pa, vol.38, pp.20-28, 2018.

K. Hatz and C. Prünte, Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration, Br J Ophthalmol, vol.100, pp.1341-1346, 2016.

O. P. Gupta, G. Shienbaum, A. H. Patel, C. Fecarotta, R. S. Kaiser et al., A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact, Ophthalmology, vol.117, pp.2134-2174, 2010.

N. Toalster, M. Russell, and P. Ng, A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration, Retina Phila Pa, vol.33, pp.1351-1359, 2013.

F. G. Holz, W. Amoaku, J. Donate, R. H. Guymer, U. Kellner et al.,

, Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study, Ophthalmology, vol.118, pp.663-71, 2011.

M. Okada, R. Kandasamy, E. W. Chong, M. Mcguiness, and R. H. Guymer, The Treat-andExtend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis, Am J Ophthalmol, vol.192, pp.184-97, 2018.

S. Fauser, V. Schwabecker, and P. S. Muether, Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration

, Am J Ophthalmol, vol.158, pp.532-538, 2014.

S. Fauser and P. S. Muether, Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times, Br J Ophthalmol, vol.100, pp.1494-1502, 2016.

P. Arendt, S. Yu, M. R. Munk, A. Ebneter, S. Wolf et al.,

. Macular-degeneration, Retina Phila Pa, 2017.

P. J. Patel, H. Devonport, S. Sivaprasad, A. H. Ross, G. Walters et al., Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update, Clin Ophthalmol Auckl NZ, vol.11, pp.1957-66, 2017.

, Résumé Évaluation en condition de vraie vie du treat and extend chez les patients atteints de dégénérescence maculaire liée à l